Novel Therapy Target in Metastatic Prostate Cancer
Sponsored by Fudan University
About this trial
Last updated a year ago
Study ID
PCa-Organoid
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
Male
Trial Timing
Started 3 years ago
What is this trial about?
The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.
What are the participation requirements?
Inclusion Criteria
1. Histologically confirmed prostate cancer
2. metastatic disease confirmed by image examination
3. Patients who can undergo surgery or biopsy for prostate cancer
4. Able to provide informed consent
Exclusion Criteria
1. Patients diagnosed with other types of cancer besides prostate cancer
2. Not accessible to surgery sample
3. Patients fail to provide informed consent
4. Other situation that researchers think are unsuitable for this study